Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Melphalan flufenamide - Oncopeptides

Next Previous
X
Search
Drug Profile

Melphalan flufenamide - Oncopeptides

Alternative Names: CK-1535; J 1; Mel-flufen; Melphalan flufenamide hydrochloride - Oncopeptides; Melphalan-prodrug-Oncopeptides; Pepaxti; PEPAXTO; Ygalo

Latest Information Update: 09 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncopeptides
  • Class Amides; Amines; Antineoplastics; Chlorinated hydrocarbons; Esters; Fluorobenzenes; Peptide drug conjugates
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase I/II Amyloid light-chain amyloidosis
  • Preclinical Acute myeloid leukaemia; Diffuse large B cell lymphoma
  • No development reported Breast cancer
  • Discontinued Cancer

Most Recent Events

  • 04 Sep 2024 Oncopeptides enters into an exclusive distribution agreement with Veld Pharmaceuticals and Slavpharma to commercialize melphalan flufenamide in Africa and Eurasia
  • 28 Jul 2024 No recent reports of development identified for preclinical development in Breast-cancer in Sweden
  • 27 Mar 2024 Oncopeptides enters into an exclusive distribution agreement with Vector Pharma to commercialize melphalan flufenamide in MENA countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top